New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SCCO;IP;MOS;ADM;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 4, 2015
07:08 EDTMOSMosaic reports Q2 EPS $1.08 vs. 64c last year
Reports Q2 revenue $2.49B vs. $2.44B last year. The year-over-year change was driven by higher phosphates operating earnings primarily as a result of higher sales volumes, and higher potash operating earnings as a result of higher realized prices and benefits from lower operating costs, partially offset by higher Canadian resource taxes.
07:02 EDTADMArcher Daniels reports Q2 adjusted EPS 60c, consensus 66c
Subscribe for More Information
August 3, 2015
14:34 EDTADMArcher Daniels volatility elevated into Q2 and outlook
Subscribe for More Information
13:51 EDTADMArcher Daniels technical comments ahead of results
Subscribe for More Information
06:05 EDTADMArcher Daniels completes sale of chocolate business to Cargill for $440M
Subscribe for More Information
July 30, 2015
07:39 EDTIPInternational Paper post-earnings selloff overdone, says Citi
Citi views yesterday's post-earnings selloff in shares of International Paper as overdone. The firm calls the Q2 results solid and reiterates a Buy rating on the stock with a $58 price target.
July 29, 2015
10:00 EDTADMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:08 EDTIPInternational Paper reports Q2 Industrial Packaging operating profits $528M
Subscribe for More Information
07:07 EDTIPInternational Paper reports Q2 operating EPS 97c, consensus 92c
Subscribe for More Information
06:49 EDTADMArcher Daniels downgraded to Neutral from Buy at Citi
Subscribe for More Information
05:28 EDTNVSNovartis announces equity stake in Mereo BioPharma Group
Novartis announced a swap of clinical assets for equity with Mereo BioPharma Group. The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under the terms of the agreement, Novartis will have an equity stake in Mereo and will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales.
July 28, 2015
15:21 EDTIPNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include MasterCard (MA), consensus 85c... Altria (MO), consensus 71... General Dynamics (GD), consensus $2.06... Anthem (ANTM), consensus $2.75... Praxair (PX), consensus $1.46... Northrop Grumman (NOC), consensus $2.36... McKesson (MCK), consensus $2.91... Eaton (ETN), consensus $1.13... Humana (HUM), consensus $1.63... Hilton (HLT), consensus 23c... International Paper (IP), consensus 92c... Rockwell Automation (ROK), consensus $1.54... Jarden (JAH), consensus 59c... Quintiles (Q), consensus 70c... Tableau Software (DATA), consensus 4c... Garmin (GRMN), consensus 82c... Vantiv (VNTV), consensus 54c... ADT (ADT), consensus 49c.
July 24, 2015
10:56 EDTNVSNovartis announces FDA approval of Odomzo
Subscribe for More Information
09:02 EDTNVSLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information
07:17 EDTNVSNovartis combination therapy Tafinlar, Mekinist achieves regulatory milestones
Subscribe for More Information
July 23, 2015
11:57 EDTIPOptions with increasing put volume
Subscribe for More Information
July 22, 2015
07:03 EDTNVSIgnyta names Bernard Parker as Chief Commercial Officer
Subscribe for More Information
July 21, 2015
11:49 EDTNVSNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
05:20 EDTNVSNovartis backs FY15 revenue guidance of up mid-single digit
Subscribe for More Information
05:17 EDTNVSNovartis reports Q2 core EPS $1.27, consensus $1.24
Reports Q2 revenue $12.7B, consensus $12.44B. Further strengthening of USD impacted sales by -11% and core operating income by -13%. Growth Products, an indicator of the rejuvenation of the portfolio, contributed 35% of continuing operations net sales in Q2, and were up 24%. In Pharmaceuticals, Growth Products contributed 44% of division net sales in the quarter, and sales for these products were up 38%.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use